Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,748.90
(0.17%)
Copper
4.30
0.87%
Oil
70.51
0.11%
Bitcoin
100,550.79
(0.63%)
FTSE 100
8,317.96
0.2%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.85
1.21%
USD/AUD
0.64
0.66%
Hang Seng
20,397.05
0.91%

Dimerix Ltd

DXB

ASX

Dimerix Limited (DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).

Latest Posts

Line Chart with Gradient
Price
$0.350
-0.025 (-6.67%)
At Close 11/12 (AEST)
Related Companies
ALTHEA GROUP HOLDINGS LIMITED
$AGH
RACE ONCOLOGY LTD
$RAC
AUSCANN GROUP HOLDINGS LTD
$AC8
AFT PHARMACEUTICALS LIMITED
$AFP
GENETIC SIGNATURES LIMITED
$GSS

Leave a Comment on DXB


Comments for DXB

    Latest Posts

    dimerix-asx-dxb-completes-fifth-idmc-review-for-action3-trial-dxb
    Health Care $DXB
    Dimerix (ASX: $DXB) completes fifth IDMC review for ACTION3 trialDimerix's DMX-200 trial for FSGS patients continues smoothly with no safety concerns reported
    November 20, 2024
    dimerix-asx-dxb-collaborates-with-neptune-to-enhance-trial-recruitment-dxb
    Health Care $DXB
    Dimerix (ASX: $DXB) collaborates with NEPTUNE to enhance trial recruitmentFocuses on Phase 3 trial for Focal Segmental Glomerulosclerosis in the United States
    November 1, 2024
    dimerix-asx-dxb-advances-phase-3-kidney-trial-dxb
    Health Care $DXB
    Dimerix (ASX: $DXB) advances phase 3 kidney trialProgressing ACTION3 trial for FSGS with strategic partners and financial backing
    October 31, 2024
    dimerix-asx-dxb-advances-fsgs-treatment-with-significant-medical-appointment-dxb
    Health Care $DXB
    Dimerix (ASX: $DXB) advances FSGS treatment with significant medical appointmentDimerix updates Project PARASOL and appoints Dr. Laura Mariani to Medical Advisory Board
    October 28, 2024
    dimerix-asx-dxb-collaborates-with-uk-registry-for-rare-kidney-diseases-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) collaborates with UK registry for rare kidney diseases

    Collaboration with RaDaR to enhance patient recruitment for ACTION3 Phase 3 trial

    September 16, 2024
    dimerix-asx-dxb-activates-first-paediatric-clinical-site-in-mexico-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) activates first paediatric clinical site in Mexico

    Recruitment of adolescent patients for Phase 3 clinical trial underway in Mexico, Argentina, UK, and US

    September 12, 2024
    dimerix-asx-dxb-initiates-dmx-200-open-label-extension-study-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) initiates DMX-200 open label extension study

    First patient enters 2-year DMX-200 OLE study after completing ACTION3 Phase 3 trial

    September 10, 2024
    dimerix-asx-dxb-receives-approval-for-paediatric-investigation-plan-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) receives approval for paediatric investigation plan

    MHRA approves DMX-200 Paediatric Investigation Plan for FSGS treatment in children

    May 1, 2024
    dimerix-asx-dxb-collects-data-for-first-interim-analysis-in-fsgs-kidney-disease-trial-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) collects data for first interim analysis in FSGS kidney disease trial

    First interim analysis data collected for DMX-200 trial in FSGS patients, Part 1 outcome expected by 15th March 2024

    February 27, 2024
    dimerix-asx-dxb-focuses-on-dmx-200-and-dmx-700-programs-dxb
    Health Care $DXB

    Dimerix (ASX: $DXB) focuses on DMX-200 and DMX-700 programs

    Reports loss of $6,673,057 for the half-year ended 31 December 2023

    February 26, 2024

    DXB

    $DXB

    Dimerix (ASX: $DXB) completes fifth IDMC review for ACTION3 trial

    Dimerix's DMX-200 trial for FSGS patients continues smoothly with no safety concerns reported

    DXB

    $DXB

    Dimerix (ASX: $DXB) collaborates with NEPTUNE to enhance trial recruitment

    Focuses on Phase 3 trial for Focal Segmental Glomerulosclerosis in the United States

    DXB

    $DXB

    Dimerix (ASX: $DXB) advances phase 3 kidney trial

    Progressing ACTION3 trial for FSGS with strategic partners and financial backing

    DXB

    $DXB

    Dimerix (ASX: $DXB) advances FSGS treatment with significant medical appointment

    Dimerix updates Project PARASOL and appoints Dr. Laura Mariani to Medical Advisory Board

    DXB

    $DXB

    Dimerix (ASX: $DXB) collaborates with UK registry for rare kidney diseases

    Collaboration with RaDaR to enhance patient recruitment for ACTION3 Phase 3 trial

    DXB

    $DXB

    Dimerix (ASX: $DXB) activates first paediatric clinical site in Mexico

    Recruitment of adolescent patients for Phase 3 clinical trial underway in Mexico, Argentina, UK, and US

    DXB

    $DXB

    Dimerix (ASX: $DXB) initiates DMX-200 open label extension study

    First patient enters 2-year DMX-200 OLE study after completing ACTION3 Phase 3 trial

    DXB

    $DXB

    Dimerix (ASX: $DXB) receives approval for paediatric investigation plan

    MHRA approves DMX-200 Paediatric Investigation Plan for FSGS treatment in children

    DXB

    $DXB

    Dimerix (ASX: $DXB) collects data for first interim analysis in FSGS kidney disease trial

    First interim analysis data collected for DMX-200 trial in FSGS patients, Part 1 outcome expected by 15th March 2024

    DXB

    $DXB

    Dimerix (ASX: $DXB) focuses on DMX-200 and DMX-700 programs

    Reports loss of $6,673,057 for the half-year ended 31 December 2023

    Related Companies
    DOMINION MINERALS LIMITED
    $DLM
    STARPHARMA HOLDINGS LIMITED
    $SPL
    ALGORAE PHARMACEUTICALS LIMITED
    $1AI
    NANOLLOSE LIMITED
    $NC6
    ONCOSIL MEDICAL LTD
    $OSL

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions